行情

PTCT

PTCT

PTC Therapeutics
NASDAQ

实时行情|Nasdaq Last Sale

51.92
-1.41
-2.64%
盘后: 52.47 +0.55 +1.07% 16:11 01/24 EST
开盘
53.56
昨收
53.33
最高
53.88
最低
51.81
成交量
50.13万
成交额
--
52周最高
54.37
52周最低
27.53
市值
32.00亿
市盈率(TTM)
-12.7866
分时
5日
1月
3月
1年
5年

分析师评级

11位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

PTCT 新闻

  • Roche's risdiplam successful in SMA study
  • seekingalpha.3天前
  • UPDATE: Cantor Fitzgerald On PTC Therapeutics Is 'confident in a May approval or earlier based on the data generated between FIREFISH and SUNFISH, and we think that an oral medicine is a game changer in this population taking intrathecal injections'
  • Benzinga.3天前
  • UPDATE: Cantor Fitzgerald Maintains Overweight On PTC Therapeutics, Raises Target To $81 As Firm Notes 'Risdiplam will be a blockbuster' Adjusts 'PoS for risdiplam to 100% from 75% and factored in the milestones in the coming years'
  • Benzinga.3天前
  • Cantor Fitzgerald Maintains Overweight on PTC Therapeutics, Raises Price Target to $81
  • Benzinga.3天前

更多

所属板块

生物技术和医学研究
-2.64%
制药与医学研究
-2.00%

热门股票

名称
价格
涨跌幅

PTCT 简况

PTC Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of medicines using its expertise in ribonucleic acid (RNA) biology. Its product pipeline includes Ataluren (Translarna), PTC596 and RG7916. Its product candidate, ataluren, is an orally administered small-molecule compound for the treatment of patients with genetic disorders due to a nonsense mutation. Ataluren is in clinical development for the treatment of Duchenne muscular dystrophy caused by a nonsense mutation (nmDMD) and cystic fibrosis caused by a nonsense mutation (nmCF). PTC596 is an orally active small molecule that targets tumor stem cell populations by reducing the function, activity and amount of BMI1. RG7916 is an investigational oral therapeutic, which is in two clinical studies: SUNFISH, a trial in childhood onset (Type II/III) spinal muscular atrophy (SMA) patients, and FIREFISH, a trial in infant onset (Type I) SMA patients.
展开

Webull提供PTC Therapeutics, Inc.的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。